Nebenwirkungen · Puregon
Puregon 300 IU/0.36 mL solution for injection Puregon 600 IU/0.72 mL solution for injection Puregon 900 IU/1.08 mL solution for injection · Abschnitt 4.8 · PDF-Seite 7
HOS-085461 · Präparat HOS-083121
Clinical use of Puregon by the intramuscular or subcutaneous routes may lead to local reactions at the site of injection (3% of all patients treated). The majority of these local reactions are mild and transient in nature. Generalised hypersensitivity reactions have been observed uncommonly (approximately 0.2% of all patients treated with follitropin beta). Cases of anaphylactic reactions (including those requiring hospitalisation) have been reported in the post-marketing setting.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-18T17:19:00Z · SHA-256 3fdd9364877a2ca4d9363213024887fcf6c4c693365f766eb9532291d20f6770 · Passage 43b9e0ed9208565e06794308366944e1a5aa0487e0445e6182b3f8b0cbf37b37 · Zeichen 0–485 im Abschnitt